Problems and methods in health care economics: is personalized medicine an exception?

被引:0
|
作者
Sickinger, Sabine [1 ]
Payne, Katherine [2 ]
Rogowski, Wolf [1 ]
机构
[1] Deutsch Forschungszentrum Gesundheit & Umwelt Gmb, Inst Gesundheitsokon & Management Gesundheitswese, Helmholtz Zentrum Munchen, D-85764 Neuherberg, Germany
[2] Univ Manchester, Inst Populat Hlth, Manchester, Lancs, England
关键词
Personalized medicine; Health economic evaluation; Evidence-based decision making; INDIVIDUALIZED CARE; DECISION-MAKING; EMPOWERMENT; INFORMATION;
D O I
10.1007/s00481-013-0266-4
中图分类号
R-052 [医学伦理学];
学科分类号
0101 ; 120402 ;
摘要
Objective For the economic evaluation of medical services, a well-established range of methods is available. The aim of this paper is to determine how and to what extent these methods are applicable to the much-discussed area of personalized medicine and which features may be encountered and how they can be addressed. Methods For this study, an exploratory literature search was conducted. Results In contrast to conventional medicine, personalized medicine might be considered either in terms of physiological differences or in terms of individual preferences of the participants. Depending on the approach, there are different implications for the methodological challenges in health economic evaluations. Improving health care provision regarding physiological differences brings up the problem of parameterization, since evidence is often very weak due to small sample sizes. Value of information analysis can reveal details about the potential benefits of further research. The concept of "expected value of individualized care" provides a very similar approach to the value of information analysis to quantify the potential value of including individual preferences in the health care provision. Welfarism and Extra Welfarism offer different solutions, such as how benefits of biomarker-based information in the sense of "empowerment" can be included in evaluations. Conclusion In general, the methods of economic evaluation are applicable to the field of personalized medicine. However, a number of specific challenges exist. Further research is necessary to solve these problems.
引用
收藏
页码:267 / 275
页数:9
相关论文
共 50 条
  • [21] PARC report: health outcomes and value of personalized medicine interventions: impact on patient care
    Mitropoulou, Christina
    Litinski, Veronika
    Kabakchiev, Boyko
    Rogers, Sara
    Patrinos, George P.
    PHARMACOGENOMICS, 2020, 21 (11) : 797 - 807
  • [22] The Economics of Health Care and Health Insurance
    Schansberg, D. Eric
    INDEPENDENT REVIEW, 2014, 18 (03) : 401 - 420
  • [23] Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies
    Trosman, Julia R.
    Weldon, Christine B.
    Douglas, Michael P.
    Deverka, Patricia A.
    Watkins, John B.
    Phillips, Kathryn A.
    VALUE IN HEALTH, 2017, 20 (01) : 40 - 46
  • [24] Multidisciplinary amyloidosis care in the era of personalized medicine
    Bumma, Naresh
    Kahwash, Rami
    Parikh, Samir V.
    Isfort, Michael
    Freimer, Miriam
    Vallakati, Ajay
    Redder, Elyse
    Campbell, Courtney M.
    Sharma, Nidhi
    Efebera, Yvonne
    Stino, Amro
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [25] Personalized medicine in primary care: the need for relevance
    Tarini, Beth A.
    Saul, Robert A.
    PERSONALIZED MEDICINE, 2013, 10 (06) : 515 - 517
  • [26] The financial hazard of personalized medicine and supportive care
    Carrera, Pricivel M.
    Olver, Ian
    SUPPORTIVE CARE IN CANCER, 2015, 23 (12) : 3399 - 3401
  • [27] The financial hazard of personalized medicine and supportive care
    Pricivel M. Carrera
    Ian Olver
    Supportive Care in Cancer, 2015, 23 : 3399 - 3401
  • [28] Knowledge and Awareness on Personalized Medicine amongst Health Care Specialists and University Students in Health Colleges in Saudi Arabia
    Ahmed, Nehad J.
    Alrawili, Abdulrahman S.
    Alkhawaja, Faisal Z.
    JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL, 2020, 32 (16) : 177 - 183
  • [29] Oncotyrol - Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research
    Siebert, Uwe
    Jahn, Beate
    Rochau, Ursula
    Schnell-Inderst, Petra
    Kisser, Agnes
    Hunger, Theresa
    Sroczynski, Gaby
    Muehlberger, Nikolai
    Willenbacher, Wolfgang
    Schnaiter, Simon
    Endel, Gottfried
    Huber, Lukas
    Gastl, Guenther
    ZEITSCHRIFT FUR EVIDENZ FORTBILDUNG UND QUALITAET IM GESUNDHEITSWESEN, 2015, 109 (4-5): : 330 - 340
  • [30] Personalized medicine in Brazil: a new paradigm, old problems
    Pavani, Claudia
    Plonski, Guilherme Ary
    INNOVATION & MANAGEMENT REVIEW, 2021, 18 (04) : 365 - 381